Ireland
featured
Ebrahim Rahbari, director of global economics at Citi Research, who coined the "Grexit" term, asks if the risks of Greece exiting the euro have really receded.
» Read More
More
-
May 20- Avon Products Inc, the beauty products direct seller, said on Monday it tapped a former Tupperware Brands Corp executive to be responsible for turning around its business in North America, where sales have been declining for years. Pablo Munoz, who was with Tupperware since 1993, most recently heading the Americas region.
-
May 20- Generic drugmaker Actavis Inc, which has been the subject of intense takeover speculation, said on Monday that it had struck a deal to buy specialty pharmaceuticals company Warner Chilcott Plc for $8.5 billion in stock.
-
DUBLIN, May 20- Elan announced its second major drug deal inside a week on Monday and said it would buy back more shares as it continues to bat against a $5.7 billion takeover bid from U.S. investor Royalty Pharma.
-
MADRID, May 19- Many duped savers at Spanish lender Bankia are shunning a state-supervised compensation scheme in favour of expensive lawsuits, prolonging a mis-selling scandal and complicating efforts to restore faith in the banking system.
-
Olli Rehn, the European Union's top economic policy maker and scourge of debt-fueled budget deficits, is fed up with austerity.
-
*France pushing to exclude audio-visual sector. BRUSSELS, May 16- European Union trade chief Karel de Gucht urged EU members on Thursday not to exclude film and television from EU-U.S. free trade talks, saying that could prompt similar action from the Americans and undermine an eventual deal.
-
MOSCOW, May 15- International leaders are moving closer to taking action on corporate tax avoidance, despite challenges, a top official at the Organisation for Economic Co-operation and Development said on Wednesday.
-
Ebrahim Rahbari, director of global economics at Citi Research, who coined the "Grexit" term, asks if the risks of Greece exiting the euro have really receded.
-
DUBLIN, May 15- Ryanair aims to grow much faster than previously indicated over the next five years in a bid to exploit the weakness of mid-tier European rivals struggling with recession, the firm's chief operating officer has told Reuters.
-
THE SPARK: Excluding one-time items, Velti posted a loss of 27 cents per share. Velti projected second-quarter revenue of between $42 million and $45 million, below Wall Street predictions of $54.3 million.
-
BRUSSELS, May 14- European Union finance ministers approved a 7.3 billion euro increase in the bloc's spending for 2013 on Tuesday, as part of a deal to unblock talks on the EU's next long-term budget. "With a view to securing the multi-annual budget, we agreed the spending increase for 2013," said Michael Noonan, Ireland's finance minister who chaired the talks.
-
BRUSSELS/ PARIS, May 14- France has secured backing from other EU member states for the exclusion of the movie and television industries from a proposed free-trade pact between Europe and the United States that it fears could threaten European culture.
-
MADRID, May 14- Order dockets found in the rubble of a Dhaka garment factory where over 1,100 workers died show just why it pays foreign stores to buy from Bangladesh- clothes made for as little as a tenth of what they sell for in the West.
-
Poland is forecast to grow in line with crisis-mired Ireland this year, as euro zone woes hit Eastern Europe.
-
Barry O'Leary, CEO of IDA Ireland, discusses what makes Ireland such "a business-friendly" country, from the low "transparent" corporate tax to the other incentives.
-
BRUSSELS, May 13- Cyprus and Malta have a lot in common: Mediterranean islands enjoying 10 months of sunshine a year, they joined the European Union in 2004, use the euro and have banking sectors that dwarf their economies.
-
NEW YORK-- Shares of Warner Chilcott PLC rose before Monday's opening bell on optimism that it will eventually reach a deal to combine with fellow drugmaker Actavis Inc..
-
DUBLIN, May 13- Irish drugmaker Elan Corporation has agreed a $1 billion royalties deal that could soothe concerns about its potentially risky acquisition strategy and fend off a takeover bid from Royalty Pharma.
-
Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21 percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline.
-
*Elan to acquire newly approved Breo as part of $1 bln deal. DUBLIN, May 13- Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21 percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline for its respiratory drugs.